evocatal invests in high-throughput technology and multiplies its screening capacity
The evocatal GmbH puts its new high-throughput screening lab located in the Life-Science Centre Duesseldorf into operation. The company multiplies its capacity for the development of new enzymes with this step. Accordingly the time-to-market period is significantly shortened through automization.
Together with the scientific advisory board and evocatal’s 17-strong team CSO Dr. Christian Leggewie opens up the newly established high-throughput laboratory in the Life Science Centre Duesseldorf.
The investment enables evocatal to reduce development periods for customized biocatalysts immensely. This applies for projects with cooperation partners as well as for supplying efficient enzymes for the internal production of fine chemicals.
Organizations
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.